Evidence map›Paper›PMID 36845645›Full record

ArticleRespiratory medicine case reports2023

A case of response to combination treatment with autologous immunotherapy and bevacizumab in advanced non-small cell lung cancer.

Thuy Mau Thi Nguyen, Khanh Van Tran, Van Thanh Ta, Linh Mai Tran, Chi Khanh Tran, Huy Le Trinh, Dat Thanh Ta, Binh Thanh Nguyen, Thinh Huy Tran

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Respiratory medicine case reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thuy Mau Thi NguyenHanoi Medical University, 1 Ton That Tung Street, Dong Da, Hanoi, Viet Nam.
Khanh Van TranHanoi Medical University, 1 Ton That Tung Street, Dong Da, Hanoi, Viet Nam.
Van Thanh TaHanoi Medical University, 1 Ton That Tung Street, Dong Da, Hanoi, Viet Nam.
Linh Mai TranUniversity of Medicine and Pharmacy, Vietnam National University Hanoi, 144 Xuan Thuy Street, Cau Giay, Hanoi, Viet Nam.
Chi Khanh TranHanoi Medical University, 1 Ton That Tung Street, Dong Da, Hanoi, Viet Nam.
Huy Le TrinhHanoi Medical University, 1 Ton That Tung Street, Dong Da, Hanoi, Viet Nam.
Dat Thanh TaHanoi Medical University, 1 Ton That Tung Street, Dong Da, Hanoi, Viet Nam.
Binh Thanh NguyenHanoi Medical University, 1 Ton That Tung Street, Dong Da, Hanoi, Viet Nam.
Thinh Huy TranHanoi Medical University, 1 Ton That Tung Street, Dong Da, Hanoi, Viet Nam.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Natural killer (NK) cells have developed as a potent tool in cancer immunotherapy. Especially, patients who have failed in the first-line or maintenance treatment received a good response with immunotherapy in association with other approaches. We report the case of a 61-year-old male patient with programmed cell death ligand - 1(PD-L1) expression in advanced non-small cell lung cancer (NSCLC) (stage IV). Even though the patient was treated with standard therapy using keytruda, he still appeared with new lesions. Therefore, the patient was treated in combination with autologous NK cells therapy, gemcitabine, bevacizumab. NK cells were expanded from peripheral blood mononuclear cells (PBMCs) of the patient, and after that, they were transferred back to the patient. After 6 infusions of autologous NK cells in combination with gemcitabine, bevacizumab, the patient decreased significantly the size of primary, metastatic lesions and had a marked improvement in the quality of life. Besides, during combination therapy, no side effects have been reported and there was no toxicity observed in the hematopoietic system, liver as well as kidneys. Our case suggests that this treatment regimen is a potential treatment approach for advanced NSCLC with PD-L1 expression.

Indexed as

Autologous natural killer cellsBevacizumabNon-small cell lung cancer (NSCLC)Programmed cell death ligand - 1 (PD-L1) expression

Identifiers

PMID36845645
PMCPMC9945779

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.